SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

DEGEN is a reward token for Farcaster users, born from meme culture. It features a unique tipping system that allows the community to reward high-quality content creators. DEGEN also powers the Degen Chain, one of the pioneering Layer 3s launched on Base. Known as the “Las Vegas of blockchains,” it provides a platform for building and using Degen apps, offering a space for fun, innovation, and community-driven experiences.

League of Degens 

DEGEN is trending as the community speculates on upcoming updates for the project's social-fi app and potential new exchange listings. Traders are closely watching key technical levels and bullish chart patterns while discussing the potential for a recovery following recent volume surges.

The Real FartCoin as suggested by Truth Terminal, following the "FartCoin Launch Strategy". Full FartCoin Ecosystem with a major focus on Planting Trees across the world.  FartNFTs,FartDAO,FartSwap and many other applications are part of our movement. With the also correct Token Mechanics such as the correct Ticker, Supply, Blockchain and Purpose of the token.  Community ran and funded, with great intentions to follow up with the full "lore" of the FartCoin!

FartCoin

FartCoin is trending as part of the broader meme coin market, with active community debate over whether it serves as a legitimate speculative asset or simply a humorous example of crypto volatility. Investors are closely monitoring its technical price levels and volume trends while comparing it to other established meme projects.

A2Z Cust2Mate Solutions Corp. is a technology company, which engages in the development and commercialization of retail smart cart solutions for large grocery stores and supermarkets. It operates through the Smart Carts and Precision Metal Parts segments. The Smart Carts segment offers retail automation solutions. Its platform enables seamless in-cart scanning and payment, allowing shoppers to bypass checkout lines while receiving real-time customized offers and product recommendations. The Precision Metal Parts segment includes the manufacturing and sale of precision metal parts. The company was founded by Joseph Bentsur on January 15, 2018 and is headquartered in Vancouver, Canada.

A2Z Cust2Mate Solutions Corp.

A2Z Smart Technologies Corp.

A2Z Smart Technologies is experiencing heightened investor scrutiny following a volatile earnings report that revealed a growing backlog of orders alongside revised financial results. While the community remains divided over the company's ability to scale smart cart deployments and manage long-term profitability, active discussions are focused on the impact of newly secured non-dilutive financing and the potential for retail media revenue to offset operational losses.

The Graph is an indexing protocol and global API for organizing blockchain data and making it easily accessible with GraphQL. Developers can use Graph Explorer to search, find, and publish all the public data they need to build decentralized applications. The Graph Network makes it possible to build serverless dApps that run entirely on public infrastructure.  GRT is the native token of the network that’s used to coordinate work. GRT is an ERC20 token. Node operators, called Indexers, stake and earn GRT for processing queries. Anyone can delegate GRT to Indexers to secure the network and earn rewards. Curators organize data on The Graph by signaling GRT on useful APIs, called subgraphs. Indexers, Delegators, and Curators work together to organize the data for the crypto economy and maintain a useful global API for DeFi and Web3.

The Graph

The Graph (GRT) is attracting significant community attention as investors position themselves for an anticipated altcoin rally, driven by its status as essential decentralized data infrastructure for Web3 and AI applications. While some users express frustration over past price performance, many are actively accumulating tokens, citing recent technical developments and high-profile integrations as indicators of long-term utility.

RoboStrategy, Inc. is a non-diversified, closed-end management investment company, which engages in investing in equity and equity-linked securities of private and public companies operating in the fields of robotics and embodied artificial intelligence. The company was founded on May 23, 2025 and is headquartered in San Juan, Puerto Rico.

RoboStrategy Inc

RoboStrategy, Inc.

RoboStrategy, Inc. is trending as traders speculate on its potential to mirror the rapid valuation growth of past high-profile IPOs and closed-end funds focused on emerging technology. The community is actively debating the fund's heavy exposure to private robotics companies and physical AI, while closely monitoring volatility and potential short-squeeze setups following recent price swings.

Jupiter is a cryptocurrency exchange platform on the Solana blockchain, offering features such as token swapping, limit orders, dollar-cost averaging, and a bridge for asset transfers to Solana. It provides users with tools to find the best trading prices and includes a beta version for perpetual futures trading. Jupiter finds the best price route for your swap by aggregating all the major liquidity sources on Solana.

Jupiter

Jupiter is experiencing significant community buzz as holders and traders leverage the platform's expanding lending and borrowing protocols, while active discussions highlight its role in the Solana ecosystem alongside trending memecoins. The community is focused on the platform's liquidity and utility, with ongoing debate surrounding tokenomics and the impact of recent market volatility on its long-term growth prospects.

Reactive Network is the first parallelized interoperability execution layer, utilising a new form of smart contract we call reactive smart contracts.   Reactive smart contracts are able to react to on-chain events autonomously and execute their own user defined logic to initiate new transactions. This allows a virtually limitless number of use cases to achieve fully decentralized on-chain automation.

Reactive Network

Reactive Network is trending as community members rally around its unique on-chain automation technology and recent cross-chain integration milestones, which have bolstered sentiment despite periods of volatility. Investors are actively discussing the potential for major exchange listings and the project's long-term utility in the Ethereum ecosystem, often sharing high-conviction outlooks regarding its future growth.

Surrozen, Inc. is a clinical stage biotechnology company, which engages in the business of discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. The company was founded by K. Christopher Garcia and Roeland Nusse on August 12, 2015 and is headquartered in South San Francisco, CA.

Surrozen Inc

Surrozen is trending as investors monitor potential buyout preparations and institutional accumulation, with community discourse centered on the company's WNT-pathway expertise and the value of its ophthalmology pipeline following recent sector acquisitions. Discussions are particularly focused on the strategic timing of pipeline updates and clinical trial milestones relative to the company's future corporate direction.

Monero

Monero is trending as market participants increasingly view it as a primary hedge against digital surveillance and the rising threat of quantum computing. The community is actively debating the privacy narrative while comparing Monero's resilience to other assets in the privacy sector amid shifting market liquidity.

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

Halozyme Therapeutics Inc.

Halozyme Therapeutics is trending following a volatile reaction to its rejected acquisition proposal for Evotec, with investors now focused on whether management will maintain capital discipline or pivot back to its core royalty-driven growth model. The community remains closely divided, balancing enthusiasm for the company's strong patent-backed revenue visibility against concerns regarding potential M&A strategy missteps and long-term litigation risks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>While the fianlimab arm showed a numerical improvement in progression-free survival, the difference was not statistically significant, Regeneron said.</li><li>The company is continuing a separate late-stage trial comparing the same combination against Bristol Myers Squibb’s Opdualag.</li><li>The setback is a disappointment for Regeneron as it tries to carve out a position in the fast-growing melanoma immunotherapy market.</li></ul>Regeneron Pharmaceuticals (REGN) shares slipped marginally in after-hours trading on Friday after the company reported that its experimental drug fianlimab, combined with its approved medicine Libtayo, failed to meet the main goal of a pivotal late-stage melanoma trial.The late-stage study tested the combination against Merck’s blockbuster drug Keytruda in patients with advanced melanoma. While the fianlimab arm showed a numerical improvement in progression-free survival, the difference was not statistically significant, Regeneron said.In the high-dose arm, patients lived a median of 11.5 months without their cancer worsening, compared with 6.4 months for those on Keytruda alone. The lower-dose arm also fell short of statistical significance. No new safety concerns were reported, the company said.Regeneron said full results will be presented at a future medical meeting. The company is continuing a separate late-stage trial comparing the same combination against Bristol Myers Squibb’s Opdualag.The setback is a disappointment for Regeneron as it tries to carve out a position in the fast-growing melanoma immunotherapy market. Fianlimab plus Libtayo remains an investigational therapy with no approved indication yet.According to data from Koyfin, 22 of the 29 analysts covering REGN stock rate it ‘Buy’ or ‘higher’ while seven rate it ‘Hold’. The average 12-month price target on the stock is $875.31, representing a potential upside of about 25% from the last close.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around REGN stock stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.A Stocktwits user opined that REGN is in a “short-term downtrend.”<stembedurl>https://www.stocktwits.com/JetSetRepeat/message/653557494</stembedurl><a href="https://stocktwits.com/symbol/REGN">REGN stock</a> has gained 19% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/cadl-stock-edges-up-after-hours-on-strong-extended-prostate-cancer-data/cZXVNHpRekL">CADL Stock Edges Up After Hours On Strong Extended Prostate Cancer Data</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Regeneron Pharmaceuticals company logo is displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Regeneron’s Drug Combo Fails To Prove Superiority Over Merck’s Keytruda In Melanoma

The company tested its experimental drug fianlimab, combined with its approved medicine Libtayo, against Merck’s Keytruda in the trial. 

Equity

Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know  

Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.

Will Keytruda Continue to Aid MRK's Growth in 2026 After a Strong Q1?

Keytruda aids Merck's Q1 performance with $8B in sales. New indications plus combo therapies could fuel the drug's overall growth through 2026.

Moderna's Revenues See Strong International Momentum in Q1 Earnings

MRNA's Q1 revenues soar 260% on strong international vaccine sales, while cost cuts and new EU approvals support its broader growth strategy.

Merck Highlights New Long-Term Data and Advancements Across Broad Oncology Portfolio and Pipeline Research at ASCO 2026

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new research from more than 100 abstracts across over 25 types of cancer from the companys comprehensive oncology portfolio and pipeline will be presented at the 2026 American Society of Clinical Oncology...

The Zacks Analyst Blog  UnitedHealth, Merck & Co., Qualcomm, EVI and Optex 

UNH, MRK and QCOM drew focus as analysts highlighted growth drivers, pipeline strength and expanding AI and automotive opportunities.

Top Research Reports for UnitedHealth, Merck & Qualcomm

UnitedHealth, Merck and QUALCOMM lead Zacks' top research picks as analysts highlight growth drivers, earnings trends and key risks.

Merck Stock Down 7% in a Month: Should Investors Hold or Exit?

Merck falls 7% despite an earnings beat as a pipeline setback and Gardasil weakness act as dampeners. However, Keytruda and new launches support growth.

Merck Scientists Publish Landmark Paper on Novel Method for Large-Scale Biocatalytic Synthesis of Investigational Oral PCSK9 Inhibitor, Enlicitide Decanoate

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today the publication of work describing the large-scale synthesis of enlicitide decanoate, the companys...

Darzalex, Erleada & New Drugs Keep J&J's Oncology Engine Charged in Q1

Darzalex and new launches fuel J&J's 17.8% oncology sales growth in Q1 as the company targets $50B in cancer sales by 2030.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

MRK
Merck & Co Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Latest MRK News

MRKMerck & Co Inc